BD
Diagnostics - TriPath
In December 2006, BD (Becton,
Dickinson and Company) acquired TriPath Imaging, Inc., a maker
of innovative solutions to
improve the clinical management of cancer. This strategic acquisition aligns
innovative new technologies
with BD’s existing business strategies and is a natural complement to
ongoing internal research
programs in its BD Diagnostics and BD Biosciences segments.
These oncology management
tools are intended to span cancer screening, diagnosis, prognosis and
therapy monitoring, especially
for cancers affecting women’s health, including breast, cervical and
ovarian. This acquisition also
demonstrates BD’s commitment to bringing new technologies and
innovation to difficult
problems in healthcare, which is in line with the Company’s purpose of “Helping
all people live healthy
lives.”
About BD
BD, a leading global medical
technology company that manufactures and sells medical devices,
instrument systems and
reagents, is dedicated to improving people’s health throughout the world.
BD is focused on improving
drug therapy, enhancing the quality and speed of diagnosing infectious
diseases, and advancing
research and discovery of new drugs and vaccines. The Company’s capabilities
are instrumental in combating
many of the world’s most pressing diseases. Founded in 1897 and
headquartered in Franklin
Lakes, New Jersey, BD employs approximately 27,000 people in approximately
50 countries throughout the
world. The Company serves healthcare institutions, life science researchers,
clinical laboratories,
industry and the general public. For more information, please visit
http://www.bd.com
Boehringer Ingelheim
is building on its long-standing research and development
capabilities and expertise in several other disease areas (e.g.,
respiratory, cardiovascular, virology and metabolic disorders),
and the strong scientific foundation provided by its research
and development centers worldwide. Several years ago,
Boehringer Ingelheim started to engage in cancer research in
response to the unmet medical needs of patients with cancer and
has made advances in understanding cancer biology. With its
cancer research and development program, Boehringer Ingelheim is
committed to discovering and developing innovative cancer
treatments that provide high therapeutic value for patients and
healthcare providers. Building on breakthrough science to
develop targeted therapies, small molecules and biologics,
Boehringer Ingelheim is focusing its research on areas of unmet
medical need, including lung, breast, ovarian, colorectal and
prostate cancers, as well as lymphomas and leukemias.
Boehringer Ingelheim
employs more than 200 scientists in its cancer research facility
at the Boehringer Ingelheim Austria Regional Centre in Vienna to
discover new cancer medicines. Promising drug candidates are
developed by the non-clinical and clinical development
organization of Boehringer Ingelheim, representing a team of
nearly 400 professionals working in oncology. Their efforts,
combined with those of leading experts in cancer research and
medicine at universities and cancer hospitals, are focused on
developing a range of next-generation therapeutics to combat
cancer. Compounds under investigation in oncology focus on
three areas: angiogenesis inhibitors, signal transduction
inhibitors and cell-cycle kinase inhibitors.
Bristol-Myers Squibb is the world leader in providing life-saving
and life-extending therapies for people with cancer. All of the
company's considerable resources and expertise in oncology are
marshaled toward the single goal of providing safer and more
effective anticancer medicines. The mission of Bristol-Myers
Squibb Oncology is to extend and enhance the lives of people
living with cancer.
http://www.BMS.com
Caris MPI provides
advanced molecular analyses of patient samples through
diagnostic and prognostic testing services using proprietary
genomic and proteomic profiling to provide critical
information to physicians treating cancer and other complex
diseases. The company has strategic relationships with the
International Genomics Research Institute and the Biodesign
Institute of Arizona State University.
www.molecularprofiling.com
Centocor Ortho Biotech Inc. redefines the
standard of care in immunology, nephrology and oncology. Built
upon a pioneering history, Centocor Ortho Biotech Inc. harnesses
innovations in large-molecule and small-molecule research to
create important new therapeutic options. Beyond its innovative
medicines, Centocor Ortho Biotech Inc. is at the forefront of
developing education and public policy initiatives to ensure
patients and their families, caregivers, advocates and
healthcare professionals have access to the latest treatment
information, support services and quality care. For more
information about Centocor Ortho Biotech Inc., visit
:www.centocororthobiotech.com
CTI is committed to developing, acquiring, and commercializing innovative
treatments for cancer. In its pursuit of making cancer more treatable, the
Company is developing a diversified portfolio of oncology drugs. Our research
and in-licensing activities are concentrated on identifying new, less toxic,
and more effective ways to treat cancer.
CTI's product pipeline includes one marketed drug, TRISENOX, and several investigational
drugs that may address the therapeutic limitations of conventional cancer therapies.
Our most advanced investigational drug, XYOTAX (polyglutamate paclitaxel), is currently
in Phase III for non-small-cell lung and ovarian cancers. Together, these drug candidates
represent our progress in making cancer a more treatable disease.
http://www.cticseattle.com
EGEN, Inc. is
a privately held biopharmaceutical company specialized in
nucleic acid (DNA, RNAi) therapeutics and delivery via
proprietary TheraPlas™ and TheraSilence™ technologies.
EGEN is
developing safe and efficient delivery systems to be used to
create products for treatment of human diseases with a focus
on cancer. The delivery systems function by protecting the
therapeutic cargo from degradation, promoting uptake by the
target cells and facilitating intracellular trafficking.
Unique chemistry and formulation strategies, designed to
overcome delivery barriers, differ substantially from other
approaches and are the distinguishing characteristics of
EGEN’s proprietary technology
EGEN’s lead product (EGEN-001) is an Immunotherapeutic
(IL-12 plasmid & TheraPlas™ delivery polymer) that has
successfully completed Phase I and Phase IA ovarian cancer
trials with favorable clinical trials response.
EGEN-001 was listed in “Top 100 Investigational Drugs” by
R&D Directions and selected to Windhover’s “Top 10 Oncology
Drugs Available for Partnering”.
Endocyte is working to
improve the diagnostic and treatment options for many types of
cancer and inflammatory disease using a new proprietary drug
guidance system (DGS). Endocyte DGS technology is designed to
target a wide variety of drugs to diseased cells while avoiding
healthy cells. Endocyte’s advanced DGS technology combines drugs
with ligands that efficiently bind to receptors overexpressed on
diseased cells. By targeting cell-surface receptors, Endocyte’s
DGS delivers potent anti-cancer agents directly to cancer cells
while avoiding delivery to healthy cells.
Exiqon
Diagnostics, a division of Exiqon A/S, is a leader in
personalizing medicine for cancer patients. Exiqon Diagnostics
is dedicated to developing and performing novel molecular and
cell-based oncology assays to help physicians individualize and
optimize treatment selection for their patients.
The Company
offers a broad range of clinical laboratory services including
the Oncotech EDR™ Assay and molecular biomarker testing. By
utilizing proprietary LNA™ technology and miRNA biomarkers,
Exiqon Diagnostics is establishing the next generation of
molecular diagnostics for oncology. Exiqon Diagnostics has
performed oncology services for more than 150,000 cancer
patients from over 1000 hospitals throughout North America and
Europe. Exiqon Diagnostics is the trade name for Oncotech,
Inc., a wholly owned subsidiary of Exiqon A/S.
www.exiqon.com
Genentech is a leading biotechnology company that
discovers, develops, manufactures and commercializes biotherapeutics for
significant
unmet medical needs. Genentech manufactures and commercializes several major
oncology drugs include Herceptin, Rituxan, Avastin and Tarceva.
http://www.genentech.com
Genzyme
Biosurgery is the leader for adhesion prevention following
abdominopelvic surgery. Seprafilm®Adhesion Barrier
is a bioresorbable, site-specific barrier that separates
adhesiogenic tissue surfaces during the critical 7-day period of
peritoneal healing. In a pivotal abdominal clinical study,
Seprafilm® Adhesion Barrier patients were 8.5 times
more likely to be free of adhesions compared to control patients
(Becker 1996). No statistically significant differences were
observed in the incidence of adverse events comparing Seprafilm®
and control patients. Sepramesh®IP Bioresorbable
Coating/Permanent Mesh is indicated for the reconstruction of
soft tissue deficiencies, such as for the repair of hernias. It
is a polypropylene mesh co-knitted with polyglycolide (PGA)
fibers, which is coated on one side with a bioresorbable HA/CMC
hydrogel that minimizes unwanted adhesions between the mesh and
underlying viscera.
http://www.genzyme.com
GlaxoSmithKline
is a world leading research based pharmaceutical company with a
powerful combination of skills and resources that provides a
platform for delivery of strong growth in today’s rapidly
changing environment. GlaxoSmithKline’s mission is to improve
the quality of human life by enabling people to do more, feel
better and live longer.
GlaxoSmithKline
also has leadership in four major therapeutic areas – anti-infectives,
central nervous system, respiratory and
gastro-intestinal/metabolic. In addition, GlaxoSmithKline is a
leader in the important area of vaccines and has a growing
portfolio of oncology products, including Hycamtin (topotecan
HCL) for relapsed ovarian cancer and Navelbine (vinorelbine
tartrate). GlaxoSmithKline Oncology also has a dedicated sales
force committed to women’s cancers, including oncology medical
scientists and oncology nurse educators.
http://www.glaxosmithkline.com
ImClone Systems Incorporated is a fully integrated
global biopharmaceutical company committed to advancing
oncology care by developing and commercializing a
portfolio of targeted biologic treatments designed to
address the medical needs of patients with a variety of
cancers.
Eli Lilly and Company is a leading innovation-driven
corporation and is developing a growing portfolio of best-in-class
pharmaceutical products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Indiana, Lilly provides
answers – through medicines and information – for some of the world’s most
urgent medical needs.
Lilly Oncology is committed to providing comprehensive healthcare
solutions – answers that matter – for oncologists and cancer patients around
the world through the discovery and development of breakthrough cancer medicines.
http://www.lilly.com
